Peptide Therapies
60 articles on Peptide Therapies, researched and written by the Shotlee Editorial Team from primary sources.
New Yorkers Are Ordering Peptides Like Takeout – And California Trim Clinic Is Behind It
New York City is experiencing a surge in peptide therapy requests via telehealth platforms. This article explores the most popular compounds, safety protocols, and how to track results effectively.
8 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
MOTS-C: A Peptide for Obesity Beyond GLP-1s?
While GLP-1 agonists have dominated weight loss discussions, a new peptide called MOTS-C is emerging with its own unique potential for tackling obesity and improving metabolic health. This article delves into what MOTS-C is, how it works, and its current research status.
7 min read
Peptides, GLP-1s, and MAHA: A New Era in Wellness
The world of wellness is rapidly evolving, with groundbreaking advancements in peptide therapy and GLP-1 medications offering new avenues for health management and weight loss. This article delves into the science behind these innovations, explores the potential of 'MAHA' (Maximum Healthspan Aging), and discusses how individuals can navigate this exciting new frontier.
9 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
FDA to Review 7 Popular Peptides Touted for Weight Loss, Healing and Longevity
The FDA Pharmacy Compounding Advisory Committee is set to evaluate seven peptide substances currently available through the gray market. Experts weigh in on safety, efficacy, and future patient access.
7 min read
US Regulators Consider Controversial Peptides Backed by RFK Jr.
The US Food and Drug Administration is evaluating the use of seven peptides, increasingly marketed for wellness and medical conditions. This review comes amidst soaring popularity, celebrity endorsements, and significant debate over their safety and efficacy.
8 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
Ozempic and Wegovy Linked to Reduced Violent Behavior in New Study
Beyond their well-known benefits for weight loss and diabetes management, popular GLP-1 medications such as Ozempic and Wegovy are now being studied for their potential impact on violent behavior. Emerging research from Rutgers University indicates a surprising link between these drugs and a reduction in actions associated with violence.
6 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Ozempic Generics Recall: Why Cheap Semaglutide Copies Are Being Pulled
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
9 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Beyond the Hype: Understanding Peptides for Weight Loss and Health
Curious about peptides and their role in weight loss, cholesterol management, and overall health? This article breaks down what peptides are, how they work, and what the science says about popular options like GLP-1 agonists.
7 min read
Beyond the Hype: Understanding GLP-1s and Weight Management
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
7 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution in Weight Loss
A closer look at the groundbreaking GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, and their transformative effects on weight management and overall health.
6 min read
Peptides: Fad or Future? Unpacking the Hype for Skin, Weight Loss & More
From celebrity endorsements to GLP-1 weight loss drugs, peptides are everywhere. But what exactly are they, and can they deliver on their promises for skin health, longevity, and more? This article dives into the science, the trends, and the risks.
7 min read
Tirzepatide vs. Semaglutide: Which Weight Loss Peptide Reigns Supreme?
The landscape of medical weight loss has been revolutionized by potent peptide therapies. Among the most talked-about are semaglutide and tirzepatide, the active ingredients in popular medications like Wegovy, Ozempic, Zepbound, and Mounjaro. But when it comes to shedding pounds, which one truly takes the lead? This article delves into the science, the studies, and the practical differences to help you understand their comparative effectiveness.
7 min read
GLP-1s and Menopause: Expert Warns of Accelerated Bone Loss Risk
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
6 min read
Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.
8 min read
Beyond Weight Loss: GLP-1 Drugs and Unexpected Changes to Taste and Smell
The revolutionary GLP-1 medications, celebrated for their efficacy in diabetes and weight management, are now being scrutinized for a less-discussed side effect: alterations in our senses of smell and taste. A recent study suggests a tangible link between these peptide therapies and sensory disturbances.
6 min read
Beyond Ozempic: Exploring the Expanding World of Peptide Therapeutics
Peptides are making waves in health and wellness, driven by the success of medications like Ozempic. This article delves into what peptides are, their growing applications, and the exciting future of peptide therapy.
8 min read
Beyond Weight Loss: How GLP-1s Like Ozempic May Impact Impulse and Behavior
While known for diabetes and weight management, GLP-1 receptor agonists like Ozempic and Wegovy might have a surprising effect on impulse control and behavior, according to emerging research.
6 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides
The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.
6 min read
Wegovy and Zepbound on Medicare: What the $50 Co-Pay Means for Your Health
A new federal agreement could lower the cost of popular weight-loss medications like Wegovy and Zepbound to $50 per month for eligible Medicare beneficiaries. Here is what you need to know about eligibility and clinical impact.
7 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.
8 min read
Beyond Weight Loss: The Expanding Horizon of GLP-1 Therapies
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
8 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Illicit Weight Loss Drug Ring Dismantled: 12,000 Doses Seized
A major bust at a country estate near Northampton has led to the seizure of 12,000 doses of illicit weight loss medications, including potent peptide drugs. Two men have been arrested as the Medicines and Healthcare products Regulatory Agency (MHRA) cracks down on dangerous counterfeit and unlicensed medicines.
6 min read
Beyond the Hype: GHK-Cu Peptide for Skin Health & Longevity
GHK-Cu peptide is gaining significant attention for its potential in skin rejuvenation and anti-aging. This article delves into what GHK-Cu is, why it's popular, and the crucial role of medical oversight in its application, moving beyond online trends to evidence-based practice.
8 min read
Beyond Ozempic: The Peptide Revolution in Health
Discover how natural peptides are challenging the pharmaceutical industry, offering a new paradigm for healing, metabolic health, and cognitive enhancement amidst evolving regulatory landscapes.
10 min read
Beyond the Injection: The Future of GLP-1 Therapies
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
7 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
GLP-1s and Hormones: Why Rapid Weight Loss Can Intensify Menopause Symptoms
Women achieving significant weight loss on GLP-1 medications like Ozempic or Wegovy often report unexpected side effects—worsening hot flashes, sleep disruption, and mood swings—that mimic or accelerate menopause symptoms. This article explores the crucial, often overlooked, intersection between rapid fat loss and hormonal balance.
8 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
GLP-1s for Weight Loss: The NHS Two-Year Limit & Private Costs
As GLP-1 agonists revolutionize weight management, many patients face a critical juncture when NHS funding ends. This article delves into the realities of these powerful medications, the challenges of long-term access, and the growing divide between publicly funded care and private treatment costs.
7 min read
Beyond the Hype: Understanding the Rise of Peptide Therapy
Peptide therapy is gaining traction, with compounds like semaglutide revolutionizing weight management. But what exactly are peptides, and what are the realities behind the trending 'peptide summer'? This article delves into the science, the risks, and the future of this evolving field.
7 min read
Beat Cravings: A Surgeon's 6-Step Guide to Lasting Fullness
Tired of constant cravings derailing your health goals? A UK surgeon reveals a simple yet effective 6-step strategy to boost satiety and minimize hunger throughout the day. Learn how to leverage the power of fiber, hydration, and smart eating habits for lasting fullness.
7 min read
Understanding Peptides: Beyond the Hype of GLP-1s and Skincare
Peptides are powerful signaling molecules, but they are not a universal cure-all. This deep dive clarifies the function of GLP-1 agonists, cosmetic peptides, and the critical importance of medical guidance when considering peptide therapies for weight management or anti-aging.
6 min read
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
FDA Warning: How to Spot Fake Tirzepatide and Stay Safe on Weight Loss
The FDA has issued a critical warning regarding counterfeit tirzepatide products. Discover the risks of fake GLP-1 medications and how to verify legitimate sources for your weight loss journey.
6 min read
Reclaiming Your Health: Beyond Weight Loss with GLP-1 Therapies
Explore the profound impact of GLP-1 medications, like semaglutide and tirzepatide, on not just weight management but also on reclaiming one's identity and overall health. Learn how these therapies can be a catalyst for significant life changes, as illustrated by personal journeys.
10 min read
Generic Semaglutide Launches in Canada: What Patients Need to Know
The Canadian market sees the arrival of a generic semaglutide injection, a significant development for individuals managing type 2 diabetes and seeking weight loss solutions. This launch by Dr. Reddy's Laboratories marks a new era of accessibility for this popular GLP-1 therapy.
7 min read
Generic Ozempic® Now Available in Canada: What You Need to Know
Apotex Inc. has launched Apo-Semaglutide Injection™, a generic version of Ozempic®, in Canada. This development brings a more affordable treatment option for type 2 diabetes management to Canadian patients and healthcare providers.
6 min read
Semaglutide for Older Adults: Weight Loss & Heart Health Gains
A comprehensive analysis of the STEP trials reveals that once-weekly semaglutide significantly benefits older adults with obesity, leading to substantial weight loss and improvements in key cardiometabolic markers. This article delves into the findings, implications, and considerations for this important demographic.
7 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
Hims & Hers Q1 Earnings: What It Means for GLP-1 Access & Weight Loss
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
7 min read
GLP-1 Medications: Understanding Ozempic, Wegovy, and Mounjaro
Celebrities and everyday individuals are increasingly discussing their experiences with GLP-1 medications such as Ozempic, Wegovy, and Mounjaro for weight management. This article delves into the science behind these popular drugs, their benefits, potential side effects, and what users can expect.
7 min read
GLP-1 Drugs & Kris Jenner: Why Some Find Them Difficult
Kris Jenner recently shared her experience with GLP-1 medications, revealing they made her feel unwell. This opens the door to understanding the nuances of these popular drugs and exploring alternative peptide therapies for weight management and overall health.
7 min read
GLP-1 Peptides: Understanding Semaglutide, Tirzepatide & More
Discover the science behind GLP-1 peptides, including semaglutide and tirzepatide, and their transformative impact on weight management and metabolic health. Learn about popular medications and how they're changing the landscape of health tracking.
7 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
GLP-1 Overdose Leads to Severe Diarrhea: A Warning
A man's harrowing experience with extreme diarrhea after overdosing on an experimental GLP-1 drug, retatrutide, serves as a stark reminder of the risks associated with obtaining and using unapproved medications outside of medical supervision. This article delves into the case, the science behind these powerful weight loss drugs, and the importance of regulated healthcare.
7 min read
Peptide Panic: Why 'Plateau Panic' Hits Hard When Suppliers Disappear
The abrupt closure of a major peptide supplier has sent shockwaves through the patient community, revealing the inherent risks of gray-market access and highlighting the critical need for regulated, physician-guided peptide therapy.
8 min read
Beyond Healthspan: The New Midlife Goal for Men
The traditional concept of retirement is being redefined as men in midlife increasingly focus on maintaining vitality and appearance, extending their 'hotspan' well into later years.
9 min read
AOD-9604: Unpacking the Metabolic Signals of a Growth Hormone Fragment
AOD-9604, a fragment of human growth hormone, is being studied for its potential to selectively influence lipid metabolism and energy balance, offering a unique lens into peptide signaling.
9 min read
GLP-1 Drugs and 'Ozempic Breath': A Sweet Twist for Hershey
The rise of GLP-1 medications like Ozempic and Wegovy is transforming health and lifestyles, but it's also leading to an unexpected side effect: 'Ozempic breath'. This phenomenon is creating a surprising boon for confectionary companies, particularly Hershey, as consumers seek relief. Learn more about this fascinating intersection of pharmaceuticals and consumer goods.
7 min read
Generic Semaglutide Approval in Canada: What It Means for Patients
Dr. Reddy's Laboratories has achieved a significant milestone by becoming the first company to receive market authorization from Health Canada for its generic semaglutide injection. This development promises to increase access to a crucial treatment option for Canadians.
6 min read
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read